Drug Profile


Alternative Names: Pre-B-cell growth factor; Pre-BSF-1

Latest Information Update: 29 Jan 2015

Price : $50

At a glance

  • Originator Amgen
  • Developer Amgen; Sanofi Winthrop
  • Class Antineoplastics; Antivirals; Interleukins
  • Mechanism of Action B cell stimulants; Interleukin 7 stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Chemoprotection; Diabetes mellitus

Most Recent Events

  • 28 Apr 1998 No-Development-Reported for Chemotherapy induced damage/Chemoprotection in USA (Unknown route)
  • 17 Apr 1997 No-Development-Reported for Diabetes mellitus in USA (Unknown route)
  • 11 Jul 1995 Preclinical development for Chemotherapy induced damage/Chemoprotection in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top